Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
This study reveals that 30.7% of atopic dermatitis patients treated with dupilumab develop ocular surface disease, despite prevalent ocular symptoms at baseline and increased ophthalmic treatment during therapy, linked to reduced conjunctiv
Cherry angiomas are significantly more prevalent and occur at younger ages in individuals with Neurofibromatosis Type 1 (NF1), linked to biallelic NF1 inactivation in vascular cells. This discovery expands the vascular phenotype of NF1 and
Brepocitinib, a selective TYK2-JAK1 inhibitor, showed rapid, sustained skin disease control, itch relief, and improved quality of life in dermatomyositis patients over 52 weeks with an acceptable safety profile in a global phase 3 trial.
We present a molecularly confirmed case of CHILD syndrome mimicking Hailey-Hailey disease without classical features, highlighting diagnostic pitfalls and benefits of targeted therapy.
Elevated serum amyloid A correlates with rapidly progressive interstitial lung disease and mortality in dermatomyositis, with combined assessment alongside anti-MDA5 antibody improving risk stratification.
Intraoperative isolation of autologous epidermal stem cells using Myseed technology improves vascularization, survival, and contraction rates of single-stage composite skin grafts in full-thickness wounds, offering a promising approach for
A randomized clinical trial shows online team-based care is as effective as conventional in-person treatment for atopic dermatitis, offering an accessible alternative for chronic disease management.
The integrated 40-gene expression profile (i40-GEP) improves risk stratification in high-risk cutaneous squamous cell carcinoma, accurately predicting metastasis and local recurrence, and identifying patients who benefit most from adjuvant
This study demonstrates that tildrakizumab, an IL-23 inhibitor, partially reverses accelerated epigenetic aging in psoriasis patients, highlighting a novel aspect of biologic therapy beyond skin inflammation control.
This review examines emerging evidence on AI-assisted LC-OCT as a noninvasive, accurate tool for detecting subclinical basal cell carcinoma in high-risk patients, highlighting diagnostic performance, subtype classification, and translationa
Emerging evidence from prospective birth cohorts reveals a dose-dependent association between early respiratory infections and the risk of childhood atopic dermatitis, independent of genetic predisposition and antibiotic exposure.
This exploratory study suggests oral dapsone benefits refractory rosacea patients, highlighting a ‘high inflammatory burden’ subtype that may predict treatment response, offering a framework for precision dermatologic care.
Two large phase 3 trials demonstrated that upadacitinib significantly improves hair regrowth and quality of life in severe alopecia areata among adolescents and adults, with a consistent and manageable safety profile.
Blood or marrow transplant recipients face an increased risk of skin cancers. This study develops validated risk models to identify high-risk patients for basal cell carcinoma, squamous cell carcinoma, and melanoma to optimize surveillance
This review synthesizes current evidence on upadacitinib for alopecia areata, focusing on long-term efficacy, safety, and predictors of treatment response, highlighting the real-world retrospective study by Wang et al. alongside emerging cl
This study details the early-onset vocal symptoms and cutaneous features of lipoid proteinosis, highlighting significant, sustained voice improvements after microlaryngosurgery and supporting early surgical intervention for optimizing patie
Updated PIVOTAL Phase III trial data demonstrate that neoadjuvant intralesional Daromun significantly improves recurrence-free and distant metastasis-free survival in resectable stage III melanoma without new safety concerns at 36.8 months
The COMBI-I trial demonstrates that adding spartalizumab to dabrafenib and trametinib improves overall survival in patients with BRAF V600-mutant advanced melanoma after over 6 years of follow-up, despite not meeting the initial progression
An expert Delphi panel established a standardized, descriptive classification for pyoderma gangrenosum (PG) to improve diagnosis, research, and treatment planning by defining distinct phenotypes and key disease modifiers.
Reflectance confocal microscopy features at week 4 post-dupilumab treatment, combined with deep learning analysis, enable non-invasive prediction of therapeutic response in facial atopic dermatitis patients.
Open language-specific specialty feeds and department pages.